Annual D&A:
$36.49M+$12.09M(+49.55%)Summary
- As of today, RXRX annual D&A is $36.49 million, with the most recent change of +$12.09 million (+49.55%) on December 31, 2024.
- During the last 3 years, RXRX annual D&A has risen by +$28.09 million (+334.19%).
- RXRX annual D&A is now at all-time high.
Performance
RXRX Depreciation & Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly D&A:
$21.04M-$2.81M(-11.77%)Summary
- As of today, RXRX quarterly D&A is $21.04 million, with the most recent change of -$2.81 million (-11.77%) on September 30, 2025.
- Over the past year, RXRX quarterly D&A has increased by +$13.85 million (+192.35%).
- RXRX quarterly D&A is now -11.77% below its all-time high of $23.85 million, reached on June 30, 2025.
Performance
RXRX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM D&A:
$77.17M+$13.85M(+21.86%)Summary
- As of today, RXRX TTM D&A is $77.17 million, with the most recent change of +$13.85 million (+21.86%) on September 30, 2025.
- Over the past year, RXRX TTM D&A has increased by +$38.02 million (+97.08%).
- RXRX TTM D&A is now at all-time high.
Performance
RXRX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
RXRX Depreciation & Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +49.5% | +192.3% | +97.1% |
| 3Y3 Years | +334.2% | +322.6% | +367.0% |
| 5Y5 Years | +1366.2% | +2355.4% | - |
RXRX Depreciation & Amortization Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +334.2% | -11.8% | +486.6% | at high | +367.0% |
| 5Y | 5-Year | at high | +1366.2% | -11.8% | +1400.9% | at high | +2250.7% |
| All-Time | All-Time | at high | +1366.2% | -11.8% | +2355.4% | at high | +8136.3% |
RXRX Depreciation & Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $21.04M(-11.8%) | $77.17M(+21.9%) |
| Jun 2025 | - | $23.85M(+23.4%) | $63.33M(+30.7%) |
| Mar 2025 | - | $19.33M(+49.3%) | $48.45M(+32.8%) |
| Dec 2024 | $36.49M(+49.6%) | $12.95M(+79.9%) | $36.49M(-6.8%) |
| Sep 2024 | - | $7.20M(-19.7%) | $39.16M(+10.2%) |
| Jun 2024 | - | $8.97M(+21.6%) | $35.55M(+4.2%) |
| Mar 2024 | - | $7.38M(-52.8%) | $34.13M(+5.1%) |
| Dec 2023 | $24.40M(+107.6%) | $15.62M(+335.3%) | $32.47M(+47.3%) |
| Sep 2023 | - | $3.59M(-52.5%) | $22.05M(-5.9%) |
| Jun 2023 | - | $7.55M(+32.0%) | $23.44M(+4.5%) |
| Mar 2023 | - | $5.72M(+10.0%) | $22.43M(+15.1%) |
| Dec 2022 | $11.76M | $5.20M(+4.4%) | $19.49M(+17.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | $4.98M(-23.9%) | $16.52M(+18.2%) |
| Jun 2022 | - | $6.54M(+136.5%) | $13.98M(+43.1%) |
| Mar 2022 | - | $2.77M(+23.7%) | $9.77M(+16.2%) |
| Dec 2021 | $8.40M(+113.2%) | $2.24M(-8.2%) | $8.40M(+36.2%) |
| Sep 2021 | - | $2.44M(+4.5%) | $6.17M(+34.4%) |
| Jun 2021 | - | $2.33M(+66.3%) | $4.59M(+39.8%) |
| Mar 2021 | - | $1.40M(+63.6%) | $3.28M(+16.5%) |
| Dec 2020 | $3.94M(+58.4%) | - | - |
| Sep 2020 | - | $857.00K(-16.3%) | $2.82M(+43.7%) |
| Jun 2020 | - | $1.02M(+9.3%) | $1.96M(+109.3%) |
| Mar 2020 | - | $937.00K | $937.00K |
| Dec 2019 | $2.49M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual D&A?
- What is the all-time high annual D&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual D&A year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly D&A?
- What is the all-time high quarterly D&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly D&A year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM D&A?
- What is the all-time high TTM D&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM D&A year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual D&A?
The current annual D&A of RXRX is $36.49M
What is the all-time high annual D&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual D&A is $36.49M
What is Recursion Pharmaceuticals, Inc. annual D&A year-on-year change?
Over the past year, RXRX annual D&A has changed by +$12.09M (+49.55%)
What is Recursion Pharmaceuticals, Inc. quarterly D&A?
The current quarterly D&A of RXRX is $21.04M
What is the all-time high quarterly D&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly D&A is $23.85M
What is Recursion Pharmaceuticals, Inc. quarterly D&A year-on-year change?
Over the past year, RXRX quarterly D&A has changed by +$13.85M (+192.35%)
What is Recursion Pharmaceuticals, Inc. TTM D&A?
The current TTM D&A of RXRX is $77.17M
What is the all-time high TTM D&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM D&A is $77.17M
What is Recursion Pharmaceuticals, Inc. TTM D&A year-on-year change?
Over the past year, RXRX TTM D&A has changed by +$38.02M (+97.08%)